These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. Nock BA; Nikolopoulou A; Reubi JC; Maes V; Conrath P; Tourwé D; Maina T J Med Chem; 2006 Jul; 49(15):4767-76. PubMed ID: 16854083 [TBL] [Abstract][Full Text] [Related]
24. Syntheses, receptor bindings, in vitro and in vivo stabilities and biodistributions of DOTA-neurotensin(8-13) derivatives containing β-amino acid residues - a lesson about the importance of animal experiments. Sparr C; Purkayastha N; Yoshinari T; Seebach D; Maschauer S; Prante O; Hübner H; Gmeiner P; Kolesinska B; Cescato R; Waser B; Reubi JC Chem Biodivers; 2013 Dec; 10(12):2101-21. PubMed ID: 24327436 [TBL] [Abstract][Full Text] [Related]
25. Imaging Neurotensin Receptor in Prostate Cancer With Deng H; Wang H; Zhang H; Wang M; Giglio B; Ma X; Jiang G; Yuan H; Wu Z; Li Z Mol Imaging; 2017; 16():1536012117711369. PubMed ID: 28849698 [TBL] [Abstract][Full Text] [Related]
26. Radiolabeled ligands specific for the G protein-coupled state of neurotensin receptors. Gaudriault G; Zsürger N; Vincent JP J Neurochem; 1996 Dec; 67(6):2590-8. PubMed ID: 8931494 [TBL] [Abstract][Full Text] [Related]
27. Catabolism of neurotensins. Implications for the design of radiolabeling strategies of peptides. Schubiger PA; Allemann-Tannahill L; Egli A; Schibli R; Alberto R; Carrel-Rémy N; Willmann M; Bläuenstein P; Tourwé D Q J Nucl Med; 1999 Jun; 43(2):155-8. PubMed ID: 10429510 [TBL] [Abstract][Full Text] [Related]
28. [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results. Maina T; Nikolopoulou A; Stathopoulou E; Galanis AS; Cordopatis P; Nock BA Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1804-14. PubMed ID: 17594090 [TBL] [Abstract][Full Text] [Related]
29. Design and structure-activity relationships of C-terminal cyclic neurotensin fragment analogues. Sefler AM; He JX; Sawyer TK; Holub KE; Omecinsky DO; Reily MD; Thanabal V; Akunne HC; Cody WL J Med Chem; 1995 Jan; 38(2):249-57. PubMed ID: 7830267 [TBL] [Abstract][Full Text] [Related]
30. Evidence of Marenco M; Lodola L; Persico MG; Frangipane V; Facoetti A; Aprile C; Hodolič M Curr Pharm Biotechnol; 2018; 19(9):754-759. PubMed ID: 30160211 [TBL] [Abstract][Full Text] [Related]
31. Development of [ Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537 [TBL] [Abstract][Full Text] [Related]
37. Receptor affinity of neurotensin message segment immobilized on liposome. Zhao J; Kimura S; Imanishi Y Biochim Biophys Acta; 1996 Jul; 1282(2):249-56. PubMed ID: 8703980 [TBL] [Abstract][Full Text] [Related]
38. Activation of neurotensin receptors and purinoceptors in human colonic adenocarcinoma cells detected with the microphysiometer. Richards M; van Giersbergen P; Zimmermann A; Lesur B; Hoflack J Biochem Pharmacol; 1997 Oct; 54(7):825-32. PubMed ID: 9353137 [TBL] [Abstract][Full Text] [Related]
39. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer. Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085 [TBL] [Abstract][Full Text] [Related]
40. Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy. Orwig KS; Lassetter MR; Hadden MK; Dix TA J Med Chem; 2009 Apr; 52(7):1803-13. PubMed ID: 19290594 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]